Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Monday

Sanara MedTech (NASDAQ:SMTI) will likely be announcing its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Sanara MedTech Price Performance

NASDAQ SMTI opened at $32.39 on Monday. The stock has a market capitalization of $283.12 million, a P/E ratio of -32.72 and a beta of 1.37. Sanara MedTech has a 1 year low of $26.00 and a 1 year high of $39.08. The business’s fifty day moving average is $34.26 and its two-hundred day moving average is $33.88. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23.

Wall Street Analyst Weigh In

Several research analysts have issued reports on SMTI shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $44.00 price target on shares of Sanara MedTech in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Sanara MedTech in a report on Thursday, January 23rd.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.